CMS specialty measure sets may be reported as an alternative to reporting 6 separate quality measures. If a measure set has less than 6 measures, eligible groups and clinicians must report all measures in the set. However, if a set has more than 6 measures, participants may choose the 6 measures that best fit their practice. Remember, at least one outcome measure must be reported, regardless of whether or not an outcome measure is included in a measure set.
|Quality Id||Measure Name||High Priority||Measure Type||Measure Description|
|239||2022 MIPS Measure #239: Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents||eCQM||Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period.||View|
|310||2022 MIPS Measure #310: Chlamydia Screening for Women||eCQM||Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period||View|
|305||2022 MIPS Measure #305: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment||eCQM||Percentage of patients 13 years of age and older with a new episode of alcohol or other drug abuse or (AOD) dependence who received the following. Two rates are reported.||View|
|379||2022 MIPS Measure #379: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists||eCQM||Percentage of children, 6 months - 20 years of age, who received a fluoride varnish application during the measurement period||View|
|382||2022 MIPS Measure #382: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment||eCQM||Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk||View|
|366||2022 MIPS Measure #366: Follow-Up Care for Children Prescribed ADHD Medication (ADD)||eCQM||Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.||View|
|065||2022 Measure # 065 Appropriate Treatment for Upper Respiratory Infection (URI)||yes||Process||Percentage of episodes for patients 3 months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event||View|
|066||2022 Measure # 066 Appropriate Testing for Pharyngitis||yes||Process||The percentage of episodes for patients 3 years and older with a diagnosis of pharyngitis that resulted in an antibiotic dispensing event and a group A streptococcus (strep) test||View|
|093||2022 Measure # 093 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use||yes||Process||Percentage of patients aged 2 years and older with a diagnosis of AOE who were not prescribed systemic antimicrobial therapy||View|
|110||2022 Measure # 110 Preventive Care and Screening: Influenza Immunization||no||Process||Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization||View|
|116||2022 Measure # 116 Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis||yes||Process||The percentage of adults 18–64 years of age with a diagnosis of acute bronchitis who were not prescribed or dispensed an antibiotic prescription||View|
|134||2022 Measure # 134 Preventive Care and Screening: Screening for Depression and Follow-Up Plan||no||Process||Percentage of patients aged 12 years and older screened for depression on the date of the encounter or 14 days prior to the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the eligible encounter||View|
|205||2022 Measure # 205 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis||no||Process||Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom chlamydia, gonorrhea, and syphilis screenings were performed at least once since the diagnosis of HIV infection||View|
|370||2022 Measure # 370 Depression Remission at Twelve Months||yes||Outcome||The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event date.||View|
|391||2022 Measure # 391 Follow-up After Hospitalization for Mental Illness (FUH)||yes||Process||The percentage of discharges for patients 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider.||View|
|394||2022 Measure # 394 Immunizations for Adolescents||no||Process||The percentage of adolescents 13 years of age who had one dose of meningococcal vaccine (serogroups A, C, W, Y), one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday.||View|
|398||2022 Measure # 398 Optimal Asthma Control||yes||Outcome||Composite measure of the percentage of pediatric and adult patients whose asthma is well-controlled as demonstrated by one of three age appropriate patient reported outcome tools and not at risk for exacerbation||View|
|402||2022 Measure # 402 Tobacco Use and Help with Quitting Among Adolescents||no||Process||The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user||View|
|464||2022 Measure # 464 Otitis Media with Effusion: Systemic Antimicrobials||yes||Process||Percentage of patients aged 2 months through 12 years with a diagnosis of OME who were not prescribed systemic antimicrobials||View|
Stay up to date with the latest news regarding MACRA and MIPS.
The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.